8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 5, 2017

NABRIVA THERAPEUTICS AG

(Exact Name of Registrant as Specified in its Charter)

Republic of Austria	001-37558	Not applicable
(State or Other Jurisdiction of Incorporation	(Commission File Number)	(IRS Employer Identification No.)

Leberstrasse 20 1110 Vienna, Austria	Not applicable
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code:  +43 (0)1 740 930

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01  Regulation FD Disclosure.

On March 27, 2017, Nabriva Therapeutics AG (the “Company”) issued a press release announcing its participation at the Needham and Company investor conference on April 5, 2017.  Information about accessing a live webcast and a subsequent replay of the Company’s presentation at the conference is included in the press release, which is attached hereto as Exhibit 99.1 and is incorporated by reference into this Form 8-K.

The Company also intends to meet with additional investors and analysts over the course of the next several weeks. A copy of the materials to be used at these meetings, which will also be referenced at the Company’s presentation at its investor conference, is attached hereto as Exhibit 99.2 and is incorporated by reference into this Form 8-K.

The information in this Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01  Financial Statements and Exhibits.

(d)Exhibits

See Exhibit Index attached hereto.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NABRIVA THERAPEUTICS AG
Date: April 5, 2017	By:	/s/ Colin Broom
		Colin Broom Chief Executive Officer

3

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release dated March 27, 2017
99.2	Presentation materials dated April 2017

4

EX-99.1

Exhibit 99.1

Nabriva Therapeutics to Present at the Needham and Company 16th Annual Healthcare Conference

VIENNA, Austria and KING OF PRUSSIA, Pa., March 27, 2017 — Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., chief executive officer of Nabriva Therapeutics, will provide a company overview and business update at the Needham and Company 16th Annual Healthcare Conference on Wednesday, April 5, 2017 at 2:20 p.m. ET. The conference is being held at the Westin New York Grand Central hotel in New York, NY.

The presentation will be webcast live and may be accessed by visiting the “Investors” section of the Company’s web site under the “Events and Presentations” tab at http://investors.nabriva.com. A replay of the webcast will be available for 90 days.

About Nabriva Therapeutics AG

Nabriva Therapeutics is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infectives to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics’ medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate. Nabriva Therapeutics’ lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The Company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Lefamulin is currently being evaluated in two global, registrational Phase 3 clinical trials in patients with moderate to severe CABP. Nabriva Therapeutics believes lefamulin is well positioned for use as a first-line empiric monotherapy for the treatment of moderate to severe CABP due to its novel mechanism of action, targeted spectrum of activity, resistance profile, achievement of substantial drug concentration in lung tissue and fluid, oral and IV formulations and a favorable tolerability profile. Nabriva Therapeutics intends to further pursue development of lefamulin for additional indications,

including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use.

Nabriva Therapeutics owns exclusive, worldwide rights to lefamulin, which is protected by composition of matter patents issued in the United States, Europe and Japan.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for Nabriva, including but not limited to statements about the development of Nabriva’s product candidates, such as plans for the design, conduct and timelines of Phase 3 clinical trials of lefamulin for CABP, the clinical utility of lefamulin for CABP and Nabriva’s plans for filing of regulatory approvals and efforts to bring lefamulin to market, the development of lefamulin for additional indications, the development of additional formulations of lefamulin, plans to pursue research and development of other product candidates, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or trials in different disease indications will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of product candidates including lefamulin for use as a first-line empiric monotherapy for the treatment of moderate to severe CABP, the sufficiency of cash resources and need for additional financing and such other important factors as are set forth under the caption “Risk Factors” in Nabriva’s annual report on Form 20-F and its prospectus supplement dated November 29, 2016 filed with the United States Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Nabriva’s views as of the date of this release. Nabriva anticipates that subsequent events and developments will cause its views to change. However, while Nabriva may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Nabriva’s views as of any date subsequent to the date of this release.

CONTACT:

INVESTOR RELATIONS

Will Sargent

Nabriva Therapeutics AG

William.Sargent@nabriva.com

610-813-6406

MEDIA

Katie Engleman

Pure Communications, Inc.

Katie@purecommunicationsinc.com

910-509-3977

EX-99.2

Exhibit 99.2

April 2017 Developing Novel Anti-Infectives

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements about our future expectations, plans and prospects, including but not limited to statements about the development of our product candidates, such as plans for the design, conduct and timelines of Phase 3 clinical trials of lefamulin for CABP, the clinical utility of lefamulin for CABP and our plans for filing of regulatory approvals and efforts to bring lefamulin to market, the development of lefamulin for additional indications, the development of additional formulations of lefamulin, plans to pursue research and development of other product candidates, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or trials in different disease indications will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of product candidates, the sufficiency of cash resources, whether research programs will result in product candidates that are advanced into future clinical trials, and need for additional financing and such other important factors as are set forth under the caption "Risk Factors" in our Annual Report on Form 10-K as filed with the United States Securities and Exchange Commission. In addition, the forward-looking statements included in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation. Safe Harbor and Disclaimer

Expert team advancing pleuromutilins, a new class of antibiotics, for systemic (IV and oral) use in humans Lefamulin in two international, pivotal Phase 3 trials for moderate-to-severe CABP with top-line data expected in 3Q17 and in 1Q18 Investing in pre-commercial activities to maximize commercial potential Cash expected to fund operations at least into 2Q18 2017- A Transformational Year for Nabriva Building a Fully Integrated Anti-Infectives Company

In 2010, direct hospitalization costs of CAP were estimated at over $17 billiona H Pneumonia is responsible for ~140,000 hospital readmissions per year, estimated to cost more than $10B in hospital expendituresb In 2013, in the US, ~50K people died due to CABPd Commercial payor average cost of ~$28K (median ~$12K) for hospitalized CABP patients over 50c Burden of Pneumonia is Increasing due to Significant Morbidity and Mortality R Sources: aFile TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122:130–41 bDe Alba Pneumonia Readmissions: Risk Factors and Implications TheOchsner Journal 14:649–654, 2014 cSato CAP Episode Costs by Age and Risk in Commercially Insured U.S. Adults Aged >50 Years Frontiers in Microbiology 2016;7:974 Appl Health Econ Health Policy (2013) 11:251–258 dHealthcare Costs and Utilization Project 2013

Significant US Adult CABP Opportunity in Hospital-Initiated Therapy ~4.2MM Oral Antibiotic Prescriptions for Hospital-Initiated Adult Outpatient CABP TreatmentB A Decision Resources Group/AMR, Age 18+ for 12 months ended December 2015 B Source Health Solutions (12 months ending September 2016), Age 18+ Nabriva Commercial Strategy Plans to Focus on Driving Early Adoption In Hospital-Initiated Patients Prioritized Hospital Formulary Acceptance Targeted Hospital Field Force ~5.3MM Orders written (avg. 4.4 days) of Inpatient IV TherapyA ~1.4MM Orders written (avg. 3.3 days) of Inpatient Oral TherapyA ~6 out of 10 Adult Outpatient Oral Prescriptions result from Hospital-Initiated CABP Treatment

Bacterial Resistance Complicates the Choice of Appropriate Empiric Therapy Sources: aMorrissey, I. ECCMID 2014. Abstract P1584 bKim, SH AAC, 2012, 56: 1418-1426 US Susceptibility Rates Have Decreased across Many Antibiotics for S. pneumoniae, the Most Common Cause of CABP Macrolide resistance is increasing for S. pneumoniaea,b globally

Achieve the best clinical outcome, while lessening or mitigating adverse events and limiting selective pressures Effective January 1, 2017, Joint Commission & CMS require that all hospitals have Antibiotic Stewardship Committees (ASC) Decrease excessive costs due to suboptimal antibiotic use Realize a fiduciary responsibility across the continuum of care IDSA/SHEA Antibiotic Stewardship guidelines for antibiotic use updated in 2016: Reduce the use of high-risk antibiotics associated with a high risk of C. Diff infections Increase use of oral antibiotics as a strategy to improve outcomes or decrease costs Reduce antibiotic therapy to the shortest effective duration Antibiotic Stewardship Should Increasingly Drive Antibiotic Choices ASC Goalsa Sources: a Policy Statement on Antimicrobial Stewardship by SHEA, IDSA, and Pediatric Infectious Diseases Society (PIDS)nfect Control Hosp Epidemiol 2012;33(4):322-327

5-7 days IV/PO Monotherapy for Most* Patients Novel Mechanism of Action CABP Targeted Spectrum of Activity Stewardship Guidelines recommend use of targeted antibiotics, not broad spectrum, and shortest effective treatment duration Resistance to many current antibiotics is rising and increases the need for antibiotics with novel mechanisms of action LEFAMULIN *10 days in clinical trials for confirmed MRSA CABP patients Lefamulin Addresses the Factors that Increasingly Influence Treatment Choices for CABP

Lefamulin A site P site PTC of the 23S rRNA of the large ribosomal subunit Pleuromutilins Represent a New Class of Antibiotics for Systemic Human Use Lefamulin: Novel mechanism of action with 4 distinctive binding sites in highly conserved core of the ribosomal peptidyl transferase center (PTC) Targeted anti-bacterial spectrum against respiratory pathogens (Gram-positive, Gram-negative and atypical bacteria) Minimal effect on off-target GI flora such as B. fragilis, E. coli and E. faecalis Low propensity for development of bacterial resistance and lack of cross-resistance with other antibiotic classes, based on in vitro studies lefamulin

Lefamulin: First in Class Systemic Pleuromutilin In Development for Targeted Empiric CABP Monotherapy Targeted spectrum of activity covering key CABP pathogens Gram-positive, Gram-negative, atypicals, including multi-drug resistant (MDR) strains Substantial penetration into lung fluids and macrophages with favorable PK/PD data Confirmed in animal models and Phase 1 studies Convenience of IV and oral formulations allowing for option to switch Enabling step down therapy and efficient patient management X-ray showing pneumonia

Lefamulin Spectrum of in vitro Activity Well Suited for CABP Extensively investigated against most prevalent pathogens Not affected by increasing antibiotic resistance observed in CABP pathogens: Cephalosporin/ fluoroquinolone/ macrolide/ penicillin resistance in S. pneumoniae Macrolide-resistant Mycoplasma spp. Note: S. pneumoniae resistant to macrolides or to levofloxacin showed 100% susceptibility to lefamulin (SENTRY 2015-16 surveillance with S. pneumoniae isolates collected world-wide) * Data from SENTRY 2015-16 world-wide surveillance program ** Waites KB et al. ASM-Microbe Meeting, June 19, 2016; Abstract#3972 Organism n MIC90 [mg/L] Organism n MIC90 [mg/L] S. pneumoniae* 2886 0.12 L. pneumophila 30 0.5 M. catarrhalis* 779 0.06 C. pneumoniae 50 0.04 H. influenzae* 1108 1 M. pneumoniae** 50 0.002 S. aureus (including HA-MRSA, CA-MRSA and MSSA) 3077 0.12

Lefamulin Data Supported Progression to Phase 3 CABP Clinical Trials CABP Animal Studies PK/PD and Microbiology Phase 2 ABSSSI Proof of Concept Phase 1/2 IV and oral data in over 400 patients and healthy subjects

Therapeutic Effect Observed in Phase 2 Trial of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Lefamulin achieved clinical response rates comparable to vancomycin Lefamulin was well tolerated Most commonly reported adverse events included headache, nausea and infusion site pain or redness Lefamulin 100 mg Lefamulin 150 mg Vancomycin 1 g N = 70 N = 71 N = 66 ITT population at Test of Cure (TOC) 85.7 83.1 81.8 CE population (N=50, 51, 51) at TOC 90.0 88.9 92.2 No increase in area of erythema plus absence of fever (%) 48-72h (ITT pop.) 85.7 83.1 80.3 20% reduction in area of erythema (%) at 48-72h (ITT pop.) 74.3 70.4 71.2 Treatment Group % response rate Lefamulin 100 mg or 150 mg IV q12h vs. vancomycin in 207 patients with ABSSSI

Lefamulin Related Tolerability Profile Observed in Phase 2 Trial of ABSSSI TABLE 10 Drug-related treatment-emergent AEs by preferred term reported by >2% of patients in ITT population  No, (%) of patients   BC-3781    100 mg 150 mg Vancomycin AE (n = 70) in = 71) 1 g(n = 66) Headache 5(7.1) 9(12.7) 10(15.2) Nausea 5(7.1) 6 (8.5) 10(15.2) Infusion site phlebitis 4 (5.7) 2 (2.8) 0 (0.0) Diarrhea 3 (4.3) 4 (5.6) 4(6.1) Vomiting 3 (4.3) 2 (2.8) 3 (4.5) Alanine aminotransferase increased 2 (2.9) 2 (2.8) 3 (4.5) Pruritus generalized 2 (2.9) 1 (1.4) 4(6.1) Creatine phosphokinase increased 2 (2.9) 1 (1-4) 0 (0.0) Phlebitis 2 (2.9) 0 (0.0) 0 (0.0) Vulvovaginal mycotic infection 2 (2.9) 0 (0.0) 0 (0,0) Abdominal pain 1 (1.4) 2 (2.8) 0 (0.0) Aspartate aminotransferase increased 1 (1.4) 1 (1.4) 2 (3.0) Pruritus 0 (0.0) 2 (2.8) 8(12.1) Infusion site pain 0 (0.0) 2 (2.8) 0 (0.0) Tinnitus 0 (0.0) 2 (2.8) 0 (0.0) Infusion site reaction 0 (0.0) 2 (2.8) 0 (0.0) Constipation 0 (0.0) 1 (1-4) 3 (4.5) Insomnia 0 (0,0) 0 (0.0) 2 (3.0)

Lefamulin Clinical Development Plan Supports Differentiation in CABP Phase 3 CABP registration program initiated in the fall of 2015 Lefamulin Evaluation of Adults with Pneumonia (LEAP 1) trial (IV to oral) in moderate-to-severe CABP (Pneumonia Outcomes Research Team (PORT) III, IV and V) Site selection planned to enrich for MDR pathogens, including MRSA February 2017- confirmation of ~550 patients sample size Second trial (LEAP 2 – oral) in moderate CABP (PORT II, III and IV) initiated April 2016 Continuing to activate sites around the globe Anticipate having ~160 sites enrolling patients Hepatic / Renal Impairment Additional Phase 1 studies LEAP 2: CABP Oral CP3, global, ~740 pts. LEAP 1: CABP IV to Oral CP3, global, ~550 pts. 2016 2018 2017 Q1 Q4 Q4 Q2 Q3 Q4 Non-Clinical Activities Blue = Clinical Programs Q3 Q2 Q1 Q3 Q2 Q1 NDA/MAA submission target in 2018

LEAP Phase 3 Trial Designs Cover Multiple Treatment Settings for CABP LEAP 1 (IV to Oral) Trial ~550 adult patients with PORT Risk Class >III (moderate to severe) 1:1 randomization: lefamulin vs. moxifloxacin ± linezolid Rx for 7 days (10 days for MRSA) PORT Risk Class III vs. IV and V >25% of patients will have a PORT risk class of IV or V Special Protocol Assessment with FDA LEAP 2 (Oral) Trial ~740 adult patients with PORT Risk Class II-IV (moderate) 1:1 randomization: lefamulin vs. moxifloxacin 5 days lefamulin / 7 days moxifloxacin PORT Risk Class II vs. III and IV >50% of patients will have a PORT risk class of III or IV Double-blind, randomized, active comparator >100 multinational centers Stratification according to: Geographic region (US vs. ex-US) Prior short-acting antibiotic therapy for CABP vs. none PORT Class

Lefamulin Fluoro-quinolones Macrolides Cephalo-sporins PCN/ BLI Tetra-cyclines Oxazo-lidinones First-in class Targeted Spectrum Activity vs. MRSA Activity vs. atypicals Activity vs. H. influenzae IV to oral switch Low Propensity for Resistance Development Empiric monotherapy Note: Nabriva management perspectives on product profiles (based on publicly available information). Lefamulin Has a Differentiated Profile in CABP Compared with Approved Classes

Financial Highlights $83.9MM Cash, cash equivalents and investments as of December 31, 2016 Pursuing plan for the redomiciliation from Austria to Ireland 2,719,695 Common shares as of Dec 19, 2016 (equivalent to ~27.2MM ADSs) Year end balance expected to fund operations at least into 2Q18

Anticipated Lefamulin Milestones February 2017 Blinded, interim analysis to confirm LEAP 1 sample size 1Q 2018 Top-line data from LEAP 2 Phase 3 trial for CABP 2H18 Regulatory filings in US and EU (priority review request to FDA) for CABP 3Q 2017 Top-line data from LEAP 1 Phase 3 trial for CABP

Advancing Pleuromutilin Development Pipeline Program Indications Discovery Pre-clinical Phase 1 Phase 2 Phase 3 Comments Lefamulin (IV/oral) CABP* LEAP 1 and LEAP 2 top-line data expected in 3Q17 and in 1Q18 ABSSSI Phase 2 complete Lefamulin (IV/oral) Pediatric Indications Preclinical work and formulation development ongoing Lefamulin (IV/oral) STIs, HABP/VABP, Osteomyelitis, Prosthetic Joint Infections Potential indications BC-7013 (Topical) uSSSI Phase 1 complete *We have not completed any clinical trials of lefamulin specifically for patients with CABP.

Lefamulin in two international, pivotal Phase 3 trials for moderate-to-severe CABP with top-line data expected in 3Q17 and in 1Q18 Investing in pre-commercial activities to maximize commercial potential Cash expected to fund operations at least into 2Q18 Key Takeaways for Transformational Year Expert team advancing pleuromutilins, a new class of antibiotic, for systemic (IV and oral) use in humans

April 2017 Developing Novel Anti-Infectives

Non-ICU Inpatient B-lactam (IV or IM) + Macrolide (IV or PO) Respiratory Quinolone (IV or PO) B-lactam (IV or IM) + Doxycycline (IV or PO) ICU Inpatient B-lactam (IV) + Macrolide (IV) B-lactam (IV) + respiratory Quinolone (IV) B-lactam (IV) + Aminoglycoside (IV) + respiratory Quinolone (IV) Mandell L. et al Clin Infect Dis. 2007; 44 (Supplement 2) :S27-S72; modified to show Community Acquired MRSA occurring in hospital, not just in ICU Outpatient If healthy, no antimicrobial use in 3 months and no Risk Factors for Drug-Resistant S. pneumoniae (DRSP) Macrolide (PO) Doxycycline (PO) Co-morbidities or Risk Factors for DRSP B-lactam (PO) + Macrolide (PO) Respiratory Quinolone (PO) At Risk for CA-MRSA Add oxazolidinone (IV) or glycopeptide (IV) Lefamulin May Be Used in Multiple CABP Treatment Settings CABP Treatment Guidelines Recommend Empiric Broad Spectrum or Combination ABx

MRSA Pneumonia Increases Patient Risk Low confirmed prevalence Difficult to distinguish clinically from other pathogens Outcomes worse than with other causative pathogens: MRSA pneumonia associated with more severe clinical outcomes than those with pneumococcal CAP1 intensive care unit admission (86.7% vs 34.8%) in-patient mortality (13.3% vs 4.4%) Empiric coverage: Some research suggests empiric therapy of severe CAP during periods of high influenza activity should include coverage for MRSA, including among those without recognized risk factors for MRSA2 Recent study in US1: although very low confirmed prevalence of S. aureus and MRSA, nearly 1/3 CABP inpatients received anti-MRSA antibiotics 1Self et al Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes Clinical Infectious Diseases Advance Access published June 2, 2016 2Hageman et al Severe community-acquired pneumonia due to Staphylococcus aureus, 2003–04 influenza season. Emerg Infect Dis. Vol. 12, No. 6, June 2006

Market Research Indicates Lefamulin Patient Opportunity from Across Generic CABP Regimens IV In-Patient Market Share 2015 Source: AMR data CEPHALOSPORIN 30% FLUOROQUINOLONE 23% MACROLIDE 17% PENICILLIN - COMBO 10% GLYCOPEPTIDE 10% AMINOGLYCOSIDE 2% TETRACYCLINE 2% CARBAPENEM 2% LINCOSAMIDE 1% MONOBACTAM 1% NITROIMIDAZOLE 1% CARBAPENEM - COMBO 1% OXAZOLIDINONE 1% PENICILLIN 0% ANTIFOLATE 0% POLYMYXIN 0% LIPOPEPTIDE 0%

Resistance and Safety Issues Could Slow Future Macrolide and Fluoroquinolone Use Source: AMR data Oral In-Patient Market Share 2015 MACROLIDE 44% FLUOROQUINOLONE 34% CEPHALOSPORIN 9% PENICILLIN - COMBO 4% TETRACYCLINE 4% ANTIFOLATE 1% OXAZOLIDINONE 1% PENICILLIN 1% LINCOSAMIDE 1% NITROIMIDAZOLE 1% RNA POLYMERASE 0%

Resistance is Growing Among Common Adult CABP Outpatient Oral Prescriptions Based on data provided by Source Health Solutions (12 months ending September 2016), Age 18+ CEFPODOXIME, 1% MINOCYCLINE, 1% MOXIFLOXACIN, 1% CLARITHROMYCIN, 1% PENICILLIN V, 1% Other, 2% CEFDINIR, 3% METRONIDAZOLE, 3% CEFUROXIME, 3% CLINDAMYCIN, 3% CEPHALEXIN, 6% CIPROFLOXACIN, 7% DOXYCYCLINE, 7% AMOXICILLIN, 8% TRIMETHOPRIM - SULFONAMIDE COMBINATION, 8% AMOXICILLIN/CLAVULANATE, 9% LEVOFLOXACIN, 19% AZITHROMYCIN, 19% Hospital Adult Oral Outpatient Market Share

LEAP 1 and 2: Powering and Primary Objectives FDA Endpoint: Early Clinical Response (ECR) 72-120 hours after first dose of study drug Intent to Treat (ITT) Population LEAP 1 non-inferiority margin 12.5%, >90% power LEAP 2 non-inferiority margin 10%, 90% power EMA endpoint: Investigator Assessment of Clinical Response (IACR) at Test of Cure 5-10 days after the last dose of study drug Modified-ITT (mITT) and Clinically Evaluable Populations LEAP 1 non-inferiority margin 10%, 80% power LEAP 2 non-inferiority margin 10%, >90% power

LEAP 1 and 2: Treatment Scenarios LEAP 1 All patients: IV therapy for a minimum of three days before switching to oral therapy Patients will receive 7 days of lefamulin vs. 7 days moxifloxacin Patients receive 10 days if: MRSA pneumonia confirmed Both moxifloxacin and linezolid started at baseline (vs. lefamulin + placebo) If MRSA identified: moxifloxacin discontinued, linezolid continued LEAP 2 All patients will receive 5 days of lefamulin vs. 7 days moxifloxacin

Lefamulin Pre-clinical Data Supports Advancing to Phase 3 for CABP 24h AUC/MIC was identified as the PK/PD index most relevant for efficacy Time-dependent killing and modest in vitro and in vivo post antibiotic effects Substantial lung penetration, as demonstrated by epithelial lining fluid and macrophage concentrations, in animal and human studies Lefamulin was efficacious in murine lung and thigh infection models predictive of efficacy in ABSSSI and bacterial respiratory tract infections Greater efficacy against S. aureus and S. pneumoniae in murine lung infection models compared to thigh infection models Overall PK/PD target attainment was >96% based on relevant PK/PD targets for both S. pneumoniae and S. aureus and robust worldwide surveillance data Results of PK/PD target attainment analyses support the lefamulin dosing regimen of 150 mg q12h IV and 600 mg q12h oral for CABP

Lefamulin Clinical Database Supported Advancing to Phase 3 for CABP Studied by IV and oral route in more than 400 patients and healthy subjects Generally well tolerated by IV and oral routes Transient, Cmax related QTc effect comparable to, or less than, that of moxifloxacin Rapid oral absorption (600mg oral q12h similar AUC to 150mg IV q12h) Achieves substantial concentrations in a variety of target tissues High penetration into human lung epithelial lining fluid and macrophages Elimination half-life of 9 to 12 hours Primarily excreted unchanged through the non-renal route Low level of metabolism Progression to Phase 3 CABP discussed with both FDA and EU regulatory authorities and follows current EMA and draft FDA guidance Amended SPA agreed with FDA on first Phase 3 (IV to oral) CABP trial

Lefamulin Manufacturing On Track for NDA Submission in 2018 Nabriva CMC/Manufacturing Team- extensive experience with new product approvals in the US and Europe Nabriva Quality Assurance Team- extensive experience with regulatory agency requirements in the US and Europe Drug Substance (API) Well known contract manufacturer in Europe with good regulatory inspection history API is very stable- expect 4-year retest date Plan to hold sufficient API inventory to reduce business interruption risk Plan to approve second API supplier to further reduce business interruption risk Drug Product (DP) Well known contract manufacturers in Europe with good regulatory inspection histories IV Product- expect 36-month shelf life with refrigerated storage Oral Product- expect 36-month shelf life with room temperature storage Plan to approve second IV and oral DP suppliers to reduce business interruption risk

Nabriva Has a Strong and Broad Patent Portfolio Nabriva currently has 19 worldwide pleuromutilin patent families active on file Most of the global pleuromutilin IP landscape is covered (including U.S., Europe, Japan) Lefamulin IP protected at least until 2028 by several layers Composition of matter granted in U.S., EP and Japan until 2028 Process patents ensure protection until 2031 Patent extension by up to 5 years in major jurisdictions BC-7013 IP protection until 2027 Composition of matter granted inter alia in U.S., EP and Japan

US legislation continues to drive discovery of novel antibiotics GAIN Act (Generating Antibiotic Incentives Now) ADAPT Act (Antibiotic Development to Advance Patient Treatment) DISARM Act (Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms)- part of 21st Century Cures Act CDC Antibiotic Resistance Threats in US, 2013 FDA CABP clinical trial guidance issued 2014 IDSA/SHEA 2016 Stewardship guidelines IDSA/ATS 2016 HAP/VAP Treatment Guidelines Recent FDA Advisory Committees for Fluoroquinolones and Solithromycin Update to 2007 IDSA/ATS CABP Treatment Guidelines in progress We believe that a need exists for novel antibiotics for infectious diseases, including CABP Scientific, Regulatory and Government Agencies Focused on Infectious Diseases

WHO Top Priority Pathogens for which New Antibiotics are Urgently Needed PRIORITY Critical Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacteriaceae carbapenem-resistant ESBL-producing PRIORITY High Staphylococcus aureus, methicillin-resistant, vancomycin-intermediate and resistant Campylobacter spp., fluoroquinolone-resistant Enterococcus faecium, vancomycin-resistant Helicobacter pylori, clarithromycin-resistant Salmonellae, fluoroquinolone-resistant PRIORITY Medium Streptococcus pneumoniae, penicillin-non-susceptible Haemophilus influenzae, ampicillin-resistant Shigella spp., fluoroquinolone-resistant Lefamulin has in vitro Activity Against Four Resistant Pathogens within WHO Priority List Neisseria gonorrhoeae, cephalosporin-resistant, fluoroquinolone-resistant Released in February 2017